Insulin Glulisine

Drug #2197

← Previous drug Next drug →

Primary Characteristics

It is of Natural origin.

Molecular Weight: 5823 · Non-proprietary name: Insulin Glulisine.

Molecular structure of Insulin Glulisine

Pharmacokinetics

Elimination: it is metabolised via Liver, renal excretion is Urine.

Indications

Insulin Glulisine is primarily indicated in conditions like Type I diabetes mellitus.

Contraindications

None recorded.

Dosage

Insulin Glulisine's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
0.75 Un it/kg	0.75 Un it/kg	Every 24h	IV	Once a day. The dose may be adjusted during stress or in case of major illness or with changes in excersie. IV should be administered under medical supervision for glycemic control with close monitoring of blood glucose and serum potassium to avoid hypoglycemia and hypokalemia.
0.75 Un it/kg	0.75 Un it/kg	Every 24h	SC	Once a day. should be given within 15 minutes before a meal or within 20 minutes after starting a meal. SC Injection should be administered in the abdiminal wall, thigh, or upper arm. To reduce the risk of lipodystrophy, rotate the injection sites within the same region.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

15 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Insulin Glulisine produces potentially life-threatening effects which include Systemic allergy. Careful monitoring is needed with proper medical management.

The signs and symptoms that are produced after acute overdosage of Insulin Glulisine are Hypoglycemic sezure, Lipodystrophy.

Insulin Glulisine is known to cause more or less tolerable side effects which are usually transient. These include Arthralgia, Edema, Headache, hyperkalemia, Hypertension , Hypoglycemia, Influenza like syndrome , Local allergies, Nasopharyngitis, Respiratory tract infections, Weight gain.

Warnings / Precautions

For all insulins, vigilance should be thaken in patients with hypoglycemia unawareness and in patients who may be prone to hypoglycemia (e.g., the pediatric population and patients who fast or have erratic food intake). The patient's ability to focus and respond may be impaired as an effect of hypoglycemia. This may present a possibility in circumstances where these abilities are especially significant, such as driving or operating other machinery. Early warning symptoms of hypoglycemia may be unlike or less obvious under certain situation, such as long term diabetic nerve disease, diabetes, use of medications such as beta-blockers (check interactions), or intensified diabetes control. These situations may result in severe hypoglycemia (and can lead to loss of consciousness) prior to the patient's awareness of hypoglycemia.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Inj

100 IU

Storage Conditions

Insulin Glulisine should be stored Unopened Vial/Cartridge (use before exp. date, discard if frozen.). Opened Vial (use within 28 days.). Opened Cartridge (Discard after 28 days.).

Drug Classification

1.18.7.1 — Insulins

Manufacturers

Manufacturers of Insulin Glulisine in Pakistan:

Aventis